The following organizations offer information about financial, travel and housing assistance for cancer patients. Each organization has their own set of guidlines regarding approval for financial assistance.
- American Cancer Society (ACS) Understanding Health Insurance, Financial Assistance for the Cancer Patient, Managing Cancer as a Chronic Illness
- Cancer Care “When you don’t know where to turn,” Cancer Care can help. If you or someone you know has just been diagnosed with carcinoid/neuroendocrine cancer—or has been living with carcinoid/neuroendocrine cancer for some time—you may have questions or need support. This website defines the five areas of service they offer for carcinoid/NET cancer patients and their families.
- National Cancer Institute (NCI) Financial Assistance for Cancer CareCancer imposes heavy economic burdens on both patients and their families. For many people, a portion of medical expenses is paid by their health insurance plan. For individuals who do not have health insurance or who need financial assistance to cover health care costs, resources are available, including Government-sponsored programs and services supported by voluntary organizations.
- Novartis Patient Assistance Program Novartis is committed to providing access to their medications for those most in need through the Novartis Pharmaceuticals Corporation’s Patient Assistance Program (PAP). PAP provides assistance to patients experiencing financial hardship who have no third party insurance coverage for their medicines.
- Novartis Sandostatin LAR Depot Co-Pay Assistance Program Effective February 2014, Novartis Pharmaceuticals Corporation has established a Co-Pay Assistance Program for carcinoid syndrome patients taking Sandostatin LAR Depot. Read more
- Ipsen Cares On December 16, 2014 the Food and Drug Administration approved Somatuline Depot (lanreotide) for treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic disease to improve progression-free survival (PFS). Ipsen Cares is a program that helps patients with coverage, access, reimbursement and education support. Read more
- LexCares Xermelo is available by prescription, in a 250 mg oral tablet, beginning on or about March 1, 2017. In an effort to ensure all appropriate patients have access to fast and affordable treatment, Lexicon has launched LexCares – a comprehensive program designed to guide patients through each step of their treatment journey. Through the LexCares Specialty Pharmacy, patients will have access to financial assistance programs that may reduce or eliminate out-of-pocket costs associated with their Xermelo prescription. For additional information, please visit www.xermelo.com/lexcares.